{"id":1306,"date":"2018-07-19T11:50:26","date_gmt":"2018-07-19T15:50:26","guid":{"rendered":"http:\/\/carolinaurologicresearchcenter.com\/?p=1306"},"modified":"2018-07-19T11:50:26","modified_gmt":"2018-07-19T15:50:26","slug":"phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer","status":"publish","type":"post","link":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/","title":{"rendered":"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer"},"content":{"rendered":"
\n
\n
\n
\n
Shilpa<\/span> Gupta<\/span><\/span>, Luke T<\/span> Nordquist<\/span><\/span>, Mark T<\/span> Fleming<\/span><\/span>, William R<\/span> Berry<\/span><\/span>, Jingsong<\/span> Zhang<\/span><\/span>, Sharon L<\/span> Ervin<\/span><\/span>, Joel R<\/span> Eisner<\/span><\/span>, Edwina S<\/span> Baskin-Bey<\/span><\/span> and Neal D<\/span> Shore<\/span><\/span><\/span><\/h5>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
click here to read article<\/strong><\/em><\/a><\/div>\n
 <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Shilpa Gupta, Luke T Nordquist, Mark T Fleming, William R Berry, Jingsong Zhang, Sharon L Ervin, Joel R Eisner, Edwina S Baskin-Bey and Neal D Shore click here to read article  <\/p>\n","protected":false},"author":1,"featured_media":1307,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[1],"tags":[],"yoast_head":"\nPhase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer - Carolina Urologic Research Center - Myrtle Beach, SC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer - Carolina Urologic Research Center - Myrtle Beach, SC\" \/>\n<meta property=\"og:description\" content=\"Shilpa Gupta, Luke T Nordquist, Mark T Fleming, William R Berry, Jingsong Zhang, Sharon L Ervin, Joel R Eisner, Edwina S Baskin-Bey and Neal D Shore click here to read article  \" \/>\n<meta property=\"og:url\" content=\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Carolina Urologic Research Center - Myrtle Beach, SC\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-19T15:50:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"625\" \/>\n\t<meta property=\"og:image:height\" content=\"521\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"CURC\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"CURC\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/\",\"name\":\"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer - Carolina Urologic Research Center - Myrtle Beach, SC\",\"isPartOf\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg\",\"datePublished\":\"2018-07-19T15:50:26+00:00\",\"dateModified\":\"2018-07-19T15:50:26+00:00\",\"author\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363\"},\"breadcrumb\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#primaryimage\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg\",\"contentUrl\":\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg\",\"width\":625,\"height\":521},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/carolinaurologicresearchcenter.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#website\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/\",\"name\":\"Carolina Urologic Research Center - Myrtle Beach, SC\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/carolinaurologicresearchcenter.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363\",\"name\":\"CURC\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/author\/curc\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer - Carolina Urologic Research Center - Myrtle Beach, SC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer - Carolina Urologic Research Center - Myrtle Beach, SC","og_description":"Shilpa Gupta, Luke T Nordquist, Mark T Fleming, William R Berry, Jingsong Zhang, Sharon L Ervin, Joel R Eisner, Edwina S Baskin-Bey and Neal D Shore click here to read article  ","og_url":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/","og_site_name":"Carolina Urologic Research Center - Myrtle Beach, SC","article_published_time":"2018-07-19T15:50:26+00:00","og_image":[{"width":625,"height":521,"url":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg","type":"image\/jpeg"}],"author":"CURC","twitter_card":"summary_large_image","twitter_misc":{"Written by":"CURC"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/","url":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/","name":"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer - Carolina Urologic Research Center - Myrtle Beach, SC","isPartOf":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg","datePublished":"2018-07-19T15:50:26+00:00","dateModified":"2018-07-19T15:50:26+00:00","author":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363"},"breadcrumb":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#primaryimage","url":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg","contentUrl":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Seviteronel..jpg","width":625,"height":521},{"@type":"BreadcrumbList","@id":"https:\/\/carolinaurologicresearchcenter.com\/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-men-with-castration-resistant-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/carolinaurologicresearchcenter.com\/"},{"@type":"ListItem","position":2,"name":"Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/carolinaurologicresearchcenter.com\/#website","url":"https:\/\/carolinaurologicresearchcenter.com\/","name":"Carolina Urologic Research Center - Myrtle Beach, SC","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/carolinaurologicresearchcenter.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363","name":"CURC","url":"https:\/\/carolinaurologicresearchcenter.com\/author\/curc\/"}]}},"_links":{"self":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/posts\/1306"}],"collection":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/comments?post=1306"}],"version-history":[{"count":0,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/posts\/1306\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/media\/1307"}],"wp:attachment":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/media?parent=1306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/categories?post=1306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/tags?post=1306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}